Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

How bad is this news for Novavax? Let's find out. Image source: Getty Images.

On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.92 which represents a decrease of $-0.08 or -0.80% from the prior close of $10. The stock opened at $10 and touched a low of ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

Novavax's shares are tumbling after the company disclosed that regulators paused clinical trials for two key vaccine ...

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...

Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...